Portolan Capital Management LLC cut its position in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 12.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,135,613 shares of the company's stock after selling 167,825 shares during the quarter. Portolan Capital Management LLC owned 1.07% of MaxCyte worth $4,724,000 as of its most recent filing with the SEC.
Other institutional investors also recently bought and sold shares of the company. Prudential Financial Inc. purchased a new position in MaxCyte in the 4th quarter valued at about $65,000. Catalyst Funds Management Pty Ltd purchased a new position in MaxCyte in the fourth quarter valued at approximately $74,000. Verition Fund Management LLC raised its stake in shares of MaxCyte by 39.5% in the 3rd quarter. Verition Fund Management LLC now owns 21,335 shares of the company's stock valued at $83,000 after acquiring an additional 6,045 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of MaxCyte by 10.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,366 shares of the company's stock worth $93,000 after purchasing an additional 2,154 shares in the last quarter. Finally, EntryPoint Capital LLC purchased a new position in MaxCyte in the 4th quarter worth approximately $185,000. 68.81% of the stock is currently owned by hedge funds and other institutional investors.
MaxCyte Stock Performance
NASDAQ:MXCT traded up $0.06 during trading hours on Friday, hitting $2.61. 472,309 shares of the company's stock traded hands, compared to its average volume of 530,875. MaxCyte, Inc. has a twelve month low of $2.21 and a twelve month high of $5.26. The stock's fifty day moving average price is $3.19 and its two-hundred day moving average price is $3.74. The firm has a market cap of $277.48 million, a P/E ratio of -7.68 and a beta of 1.39.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on MXCT. BTIG Research set a $6.00 target price on MaxCyte and gave the company a "buy" rating in a research report on Wednesday, March 12th. Stifel Nicolaus reduced their price objective on shares of MaxCyte from $11.00 to $9.00 and set a "buy" rating on the stock in a research note on Wednesday, March 12th.
Get Our Latest Analysis on MaxCyte
About MaxCyte
(
Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Featured Stories
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
